Kurt Von Emster Sells 108,876 Shares of CymaBay Therapeutics Inc. (CBAY) Stock
CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Kurt Von Emster also recently made the following trade(s):
- On Friday, September 29th, Kurt Von Emster sold 211,124 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16.
CymaBay Therapeutics Inc. (NASDAQ:CBAY) opened at 8.08 on Friday. The company’s market cap is $353.55 million. The firm has a 50-day moving average price of $6.94 and a 200 day moving average price of $5.47. CymaBay Therapeutics Inc. has a 52 week low of $1.15 and a 52 week high of $8.45.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.06). Analysts expect that CymaBay Therapeutics Inc. will post ($0.82) EPS for the current fiscal year.
Several research analysts have recently weighed in on CBAY shares. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Cantor Fitzgerald began coverage on CymaBay Therapeutics in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 target price for the company. Leerink Swann began coverage on CymaBay Therapeutics in a research note on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 target price for the company. Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Finally, Piper Jaffray Companies set a $7.00 target price on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.00.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after buying an additional 170,126 shares in the last quarter. Boxer Capital LLC purchased a new stake in CymaBay Therapeutics in the first quarter worth about $3,342,000. Renaissance Technologies LLC increased its position in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 114,549 shares in the last quarter. Ardsley Advisory Partners increased its position in CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 20,000 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in CymaBay Therapeutics in the second quarter worth about $242,000. Institutional investors and hedge funds own 25.91% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.